The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.
Ozempic: Weight-Loss Drug's Benefits And Risks Revealed in New Study
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
Weight-loss drugs like Ozempic could also help fight dementia but raise other health risks, study says
Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and other medications like it have a host of other potential health benefits beyond obesity,
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Despite low obesity rate, Mass. has the third-highest increase in weight-loss drug prescriptions nationwide. Why?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.
Weight-loss drugs may boost health in many ways
The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million people,
Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Medicare announces weight-loss drugs, including Ozempic, will be up for price negotiations
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Can't Afford Ozempic? A Complete Guide to Other Effective Weight Loss Alternatives
From science-backed supplements to insurance-covered nutrition therapy, here's your complete guide to effective weight loss ...
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...